Used in targeted cancer therapy, particularly in the treatment of advanced solid tumors and thyroid cancer. Acts as a selective inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptor (PDGFR), and stem cell factor receptor (KIT). By blocking these receptors, it interferes with tumor angiogenesis and cell proliferation, thereby suppressing tumor growth and metastasis. Investigated in clinical trials for non-small cell lung cancer and other malignancies due to its ability to disrupt signaling pathways critical for tumor survival. Its oral bioavailability makes it a convenient option for long-term treatment regimens in oncology.